Seniors with Parkinson’s Disease: Initial Medical Treatment

키워드

참고문헌 (85)

1. Elbaz A, "Risk tables for parkinsonism and Parkinson’s disease", J Clini Epidemiol, 55, pp.25~31 (2002)
2. Muslimovic D, "Cognitive profile of patients with newly diagnosed Parkinson disease", Neurology, 65, pp.1239~1245 (2005)
3. Mamikonyan E, "Mild cognitive impairment is common in Parkinson’s disease patients with normal Mini-Mental State Examination(MMSE)scores", Parkinsonism Relat Disord, 15, pp.226~231 (2009)
4. Aarsland D, "Cognitive impairment in incident,untreated Parkinson disease:the Norwegian ParkWest study", Neurology, 72, pp.1121~1126 (2009)
5. Hely MA, "Sydney Multicenter Study of Parkinson’s disease:non-L-dopa-responsive problems dominate at 15 years", Mov Disord, 20, pp.190~199 (2005)
6. Buter TC, "Dementia and survival in Parkinson disease:a 12-year population study", Neurology, 70, pp.1017~1022 (2008)
7. Mayeux R, "An estimate of the incidence of dementia in idiopathic Parkinson’s disease", Neurology, 40, pp.1513~1517 (1990)
8. Hurtig HI, "Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease", Neurology, 54, pp.1916~1921 (2000)
9. Apaydin H, "Parkinson disease neuropathology:later-developing dementia and loss of the levodopa response", Arch Neurol, 59, pp.102~112 (2002)
10. Aarsland D, "Neuropathology of dementia in Parkinson’s disease:a prospective,community-based study", Ann Neurol, 58, pp.773~776 (2005)
11. Braak H, "Cognitive status correlates with neuropathologic stage in Parkinson disease", Neurology, 64, pp.1404~1410 (2005)
12. Kramer ML, "Presynaptic alpha-synuclein aggregates,not Lewy bodies,cause neurodegeneration in dementia with Lewy bodies", J Neurosci, 27, pp.1405~1410 (2007)
13. Abbott RD, "Frequency of bowel movements and the future risk of Parkin son’s disease", Neurology, 57, pp.456~462 (2001)
14. Savica R, "Medical records documentation of constipation preceding Parkinson disease:A case-control study", Neurology, 73, pp.1752~1758 (2009)
15. Braak H, "Gastric alpha-synuclein immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in cases staged for Parkinson’s disease-related brain pathology", Neurosci Lett, 396, pp.67~72 (2006)
16. Braak H, "Parkinson’s disease:lesions in dorsal horn layer I,involvement of parasympathetic and sympathetic pre-and postganglionic neurons", Acta Neuropathol, 113, pp.421~429 (2007)
17. Klos KJ, "Alpha-synuclein pathology in the spinal cords of neurologically asymptomatic aged individuals", Neurology, 66, pp.1100~1102 (2006)
18. Bloch A, "Alpha-synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects", Neuropathol Appl Neurobiol, 32, pp.284~295 (2006)
19. Ahlskog JE, "Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature", Mov Disord, 16, pp.448~458 (2001)
20. Chase TN, "The significance of continuous dopaminergic stimulation in the treatment of Parkinson’s disease", Drugs 55 Supple, 1, pp.1~9 (1998)
21. Effect of deprenyl on the progression of disability in early Parkinson’s disease, "The Parkinson Study Group", N Engl J Med, 321, pp.1364~1371 (1989)
22. "Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease.The Parkinson Study Group", N Engl J Med, 328, pp.176~183 (1993)
23. "Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP subjects not requiring levodopa.Parkinson Study Group", Ann Neurol, 39, pp.29~36 (1996)
24. "Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP patients requiring levodopa.Parkinson Study Group", Ann Neurol, 39, pp.37~45 (1996)
25. Ahlskog JE, "Slowing Parkinson’s disease progression:recent dopamine agonist trials", Neurology, 60, pp.381~389 (2003)
26. Parkinson Study Group, "Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression", JAMA, 287, pp.1653~1661 (2002)
27. Whone AL, "Slower progression of Parkinson’s disease with ropinirole versus levodopa:The REAL-PET study", Ann Neurol, 54, pp.93~101 (2003)
28. Olanow CW, "TCH346 as a neuroprotective drug in Parkinson’s disease:a double-blind,randomized,controlled trial", Lancet Neurol, 5, pp.1013~1020 (2006)
29. Parkinson Study Group PRECEPT Investigators, "Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease", Neurology, 69, pp.1480~1490 (2007)
30. Suchowersky O, "Practice Parameter:neuroprotective strategies and alternative therapies for Parkinson disease(an evidence-based review):report of the Quality Standards Subcommittee of the American Academy of Neurology", Neurology, 66, pp.976~982 (2006)
31. Olanow CW, "A double-blind,delayed-start trial of rasagiline in Parkinson’s disease", N Engl J Med, 361, pp.1268~1278 (2009)
32. Ahlskog JE, "Rasagiline,Parkinson neuroprotection,and delayed-start trials:still no satisfaction?", Neurology, 74, pp.1143~1148 (2010)
33. Tilley BC, "Optimizing the ongoing search for new treatments for Parkinson disease:using futility designs", Neurology, 66, pp.628~633 (2006)
34. Diamond SG, "Present morality in parkinson’s disease:the ratio of observed to expected deaths with a method to calculate expected deaths", J Neural Transm, 38, pp.259~269 (1976)
35. Hoehn MM, "Parkinson’s disease:progression and mortality", Adv Neurol, 45, pp.457~461 (1986)
36. Joseph C, "Levodopa in Parkinson’s disease:a long-term appraisal of mortality", Ann Neurol, 3, pp.116~118 (1978)
37. Martilla RJ, "Mortality of patients with Parkinson’s disease treated with levodopa", J Neurol, 216, pp.147~153 (1977)
38. Sweet RD, "Five years’ treatment of Parkinson’s disease with levodopa.Therapeutic results and survival of 100 patients", Ann Intern Med, 83, pp.456~463 (1975)
39. Uitti RJ, "Levodopa therapy and survival in idiopathic Parkinson’s disease:Olmsted County project", Neurology, 43, pp.1918~1926 (1993)
40. Zumstein H, "Mortality among Parkinson patients treated with L-dopa combined with a decarboxylase inhibitor", Eur Neurol, 14, pp.321~328 (1976)
41. Rajput AH, "Timely levodopa(LD)administration prolongs survival in Parkinson’s disease", Parkinsonism Relat Disord, 3, pp.159~165 (1997)
42. Elbaz A, "Survival study of Parkinson disease in Olmsted County,Minnesota", Arch Neurol, 60, pp.91~96 (2003)
43. Braak H, "Staging of brain pathology related to sporadic Parkinson’s disease", Neurobiol Aging, 24, pp.197~211 (2003)
44. Braak H, "Stages in the development of Parkinson’s disease-related pathology", Cell Tissue Res, 318, pp.121~134 (2004)
45. Fahn S, "The oxidant stress hypothesis in Parkinson’s disease:evidence supporting it", AnnNeurol, 32, pp.804~812 (1992)
46. Olanow CW, "Oxidation reactions in Parkinson’s disease", Neurology, 40(Suppl), pp.32~37 (1990)
47. Clement MV, "The cytotoxicity of dopamine may be an artefact of cell culture", J Neurochem, 81, pp.414~421 (2002)
48. Ahlskog JE, "Challenging conventional wisdom:the etiologic role of dopamine oxidative stress in Parkinson’s disease", Mov Disord, 20, pp.271~282 (2005)
49. Ahlskog JE, "Beating a dead horse:dopamine and Parkinson disease", Neurology, 69, pp.1701~1711 (2007)
50. Fahn S, "Levodopa and the progression of Parkinson’s disease", N Engl J Med, 351, pp.2498~2508 (2004)
51. Damier P, "The substantia nigra of the human brain.II.Patterns of loss of dopamine-containing neurons in Parkinson’s disease", Brain, 122, pp.1437~1448 (1999)
52. Ahlskog JE, "Parkinson’s Disease Treatment Guide for Physicians" (2009), Oxford University Press
53. Poewe WH, "Low-dose L-dopa therapy in Parkinson’s disease:a 6-year follow-up study", Neurology, 36, pp.1528~1530 (1986)
54. Bonuccelli U, "Role of dopamine receptor agonists in the treatment of early Parkinson’s disease", Parkinsonism Relat Disord, 15(Suppl,4), pp.S44~S53 (2009)
55. Schapira AH, "Drug selection and timing of initiation of treatment in early Parkinson’s disease", Ann Neurol, 64(Suppl,2), pp.S47~S55 (2008)
56. Quinn N, "Young onset Parkinson’s disease", Mov Disord, 2, pp.73~91 (1987)
57. Schrag A, "Youngonset Parkinson’s disease revisited-clinical features,natural history,and mortality", Mov Disord, 13, pp.885~894 (1998)
58. Kumar N, "Levodopa-dyskinesia incidence by age of Parkinson’s disease onset", Mov Disord, 20, pp.342~344 (2005)
59. Van Gerpen JA, "Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County,Minnesota,1976-1990", Arch Neurol, 63, pp.205~209 (2006)
60. Rinne UK, "Early treatment of Parkinson’s disease with cabergoline delays the onset of motor complications.Results of a double-blind levodopa controlled trial.The PKDS009 Study Group", Drugs 55 Suppl, 1, pp.23~30 (1998)
61. Rascol O, "A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa.056 Study Group", N Engl J Med, 342, pp.1484~1491 (2000)
62. Parkinson Study Group, "Pramipexole vs levodopa as intial treatment for Parkinson disease:A randomized controlled trial.Parkinson Study Group", JAMA, 284, pp.1931~1938 (2000)
63. Holloway RG, "Pramipexole vs levodopa as initial treatment for Parkinson disease:a 4-year randomized controlled trial", Arch Neurol, 61, pp.1044~1053 (2004)
64. Oertel WH, "Pergolide versus levodopa monotherapy in early Parkinson’s disease patients:The PELMOPET study", Mov Disord, 21, pp.343~353 (2006)
65. Lieberman A, "Treatment of parkinson’s disease with bromocriptine", N Engl J Med, 295, pp.1400~1404 (1976)
66. Lieberman A, "Long-term efficacy of bromocriptine in Parkinson disease", Neurology, 30, pp.518~523 (1980)
67. Olanow CW, "A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson’s disease", Mov Disord, 9, pp.40~47 (1994)
68. Frucht S, "Falling asleep at the wheel:motor vehicle mishaps in persons taking pramipexole and ropinirole", Neurology, 52, pp.1908~1910 (1999)
69. Driver-Dunckley E, "Pathological gambling associated with dopamine agonist therapy in Parkinson’s disease", Neurology, 61, pp.422~423 (2003)
70. Dodd ML, "Pathological gambling caused by drugs used to treat Parkinson disease", Arch Neurol, 62, pp.1377~1381 (2005)
71. Klos KJ, "Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson’s disease and multiple system atrophy", Parkinsonism Relat Disord, 11, pp.381~386 (2005)
72. Nirenberg MJ, "Compulsive eating and weight gain related to dopamine agonist use", Mov Disord, 21, pp.524~529 (2006)
73. Voon V, "Prevalence of repetitive and reward-seeking behaviors in Parkinson disease", Neurology, 67, pp.1254~1257 (2006)
74. McKeon A, "Unusual compulsive behaviors primarily related to dopamine agonist therapy in Parkinson’s disease and multiple system atrophy", Parkinsonism Relat Disord, 13, pp.516~519 (2007)
75. Bostwick JM, "Frequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson disease", Mayo Clin Proc, 84, pp.310~316 (2009)
76. Nissinen H, "Early versus delayed initiation of entacapone in levodopa-treated patients with Parkinson’s disease:a long-term,retrospective analysis", Eur J Neurol, 16, pp.1305~1311 (2009)
77. Hauser RA, "Double-blind trial of levodopa", carbidopa, carbidopa in early Parkinson’s disease, pp.Mov Disord, 2009[DOI]
78. Ruottinen HM, "Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations", J Neurol Neurosurgery Psychiatry, 60, pp.36~40 (1996)
79. Dupont E, "Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients", Acta Neurol Scand, 93, pp.14~20 (1996)
80. Block G, "Comparison of immediate-release and controlled release carbidopa", levodopa in Parkinson’s disease.A multicenter 5-year study.The CR First Study Group, 1997, pp.37, 23~27
81. Ahlskog JE, "Controlled-release Sinemet(CR-4):a double-blind crossover study in patients with fluctuating Parkinson’s disease", Mayo Clin Proc, 63, pp.876~886 (1988)
82. Yeh KC, "Pharmacokinetics and bioavailability of Sinemet CR:a summary of human studies", Neurology, 39, pp.25~38 (1989)
83. Pincus JH, "Influence of dietary protein on motor fluctuations in Parkinson’s disease", Arch Neurol, 44, pp.270~272 (1987)
84. Muenter MD, "L-dopa therapy of Parkinson’s disease:plasma L-dopa concentration,therapeutic response,and side effects", Mayo Clin Proc, 46, pp.231~239 (1971)
85. Shiba M, "Anxiety disorders and depressive disorders preceding Parkinson’s disease:a case-control study", Mov Disord, 15, pp.669~677 (2000)

관련 논문AI추천